{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tetanus+Toxoid+Vaccine&page=7",
    "query": {
      "intervention": "Tetanus Toxoid Vaccine",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 182,
    "total_pages": 19,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tetanus+Toxoid+Vaccine&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tetanus+Toxoid+Vaccine&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-09T01:36:19.038Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05470400",
      "title": "A Clinical Trial to Evaluate Safety, Tolerability, and Immunogenicity of Adjuvanted HIV-1 Fusion Peptide Conjugate Vaccine Alone or in Prime-Boost Regimens With Adjuvanted HIV-1 Envelope Trimer 4571 and HIV-1 Trimer 6931 Vaccines in Healthy Adults",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV"
      ],
      "interventions": [
        {
          "name": "FP conjugate vaccine (25 mcg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "FP conjugate vaccine (200 mcg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Trimer 6931 (100 mcg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Trimer 6931 (200 mcg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Trimer 4571 (200 mcg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Trimer 4571 (100 mcg)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 44,
      "start_date": "2022-08-15",
      "completion_date": "2024-01-24",
      "has_results": true,
      "last_update_posted_date": "2026-04-23",
      "last_synced_at": "2026-10-09T01:36:19.038Z",
      "location_count": 6,
      "location_summary": "Atlanta, Georgia • Boston, Massachusetts • New York, New York + 2 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05470400"
    },
    {
      "nct_id": "NCT00071981",
      "title": "Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma (Skin)"
      ],
      "interventions": [
        {
          "name": "incomplete Freund's adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "melanoma helper peptide vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "multi-epitope melanoma peptide vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "tetanus peptide melanoma vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Eastern Cooperative Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 175,
      "start_date": "2005-05-09",
      "completion_date": "2014-01",
      "has_results": true,
      "last_update_posted_date": "2023-06-28",
      "last_synced_at": "2026-10-09T01:36:19.038Z",
      "location_count": 65,
      "location_summary": "Palo Alto, California • Stanford, California • Lewes, Delaware + 50 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Lewes",
          "state": "Delaware"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00071981"
    },
    {
      "nct_id": "NCT04006457",
      "title": "Long-Term PF-06651600 for the Treatment of Alopecia Areata",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alopecia Areata"
      ],
      "interventions": [
        {
          "name": "PF-06651600",
          "type": "DRUG"
        },
        {
          "name": "Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 1057,
      "start_date": "2019-07-18",
      "completion_date": "2026-02-26",
      "has_results": true,
      "last_update_posted_date": "2026-04-09",
      "last_synced_at": "2026-10-09T01:36:19.038Z",
      "location_count": 47,
      "location_summary": "Birmingham, Alabama • Beverly Hills, California • Irvine, California + 28 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04006457"
    },
    {
      "nct_id": "NCT02737475",
      "title": "An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Cancer"
      ],
      "interventions": [
        {
          "name": "BMS-986178",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Tetanus vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "DPV-001 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 166,
      "start_date": "2016-06-17",
      "completion_date": "2020-11-02",
      "has_results": true,
      "last_update_posted_date": "2022-01-25",
      "last_synced_at": "2026-10-09T01:36:19.038Z",
      "location_count": 8,
      "location_summary": "Aurora, Colorado • Washington D.C., District of Columbia • Hackensack, New Jersey + 4 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02737475"
    },
    {
      "nct_id": "NCT00467519",
      "title": "Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Tetanus",
        "Diphtheria",
        "Pertussis"
      ],
      "interventions": [
        {
          "name": "Tdap (Tetanus Toxoid Reduced Diphtheria Toxoid/Acellular Pertussis)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "DTaP (Diphtheria & Tetanus Toxoids & Acellular Pertussis Adsorbed)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "6 Years",
        "sex": "ALL",
        "summary": "4 Years to 6 Years"
      },
      "enrollment_count": 1045,
      "start_date": "2007-04",
      "completion_date": "2009-12",
      "has_results": true,
      "last_update_posted_date": "2014-02-07",
      "last_synced_at": "2026-10-09T01:36:19.038Z",
      "location_count": 42,
      "location_summary": "Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 34 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00467519"
    },
    {
      "nct_id": "NCT00369824",
      "title": "Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Infections, Papillomavirus"
      ],
      "interventions": [
        {
          "name": "Different formulations of GSK Biologicals' HPV vaccine (580299)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Menactra TM",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Boostrix TM",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "11 Years",
        "maximum_age": "18 Years",
        "sex": "FEMALE",
        "summary": "11 Years to 18 Years · Female only"
      },
      "enrollment_count": 1330,
      "start_date": "2006-09-26",
      "completion_date": "2008-02-13",
      "has_results": true,
      "last_update_posted_date": "2018-07-20",
      "last_synced_at": "2026-10-09T01:36:19.038Z",
      "location_count": 50,
      "location_summary": "Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 46 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00369824"
    },
    {
      "nct_id": "NCT00977145",
      "title": "Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "A combination of intratumoral IFN-gamma plus systemic vaccination with MELITAC 12.1",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Craig L Slingluff, Jr",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2009-11",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2016-12-16",
      "last_synced_at": "2026-10-09T01:36:19.038Z",
      "location_count": 1,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00977145"
    },
    {
      "nct_id": "NCT00258895",
      "title": "Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old After 4 Doses of Pentacel™ or DAPTACEL®",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diphtheria",
        "Tetanus",
        "Pertussis"
      ],
      "interventions": [
        {
          "name": "DAPTACEL®: DTaP",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "6 Years",
        "sex": "ALL",
        "summary": "4 Years to 6 Years"
      },
      "enrollment_count": 649,
      "start_date": "2005-03",
      "completion_date": "2007-04",
      "has_results": true,
      "last_update_posted_date": "2016-04-14",
      "last_synced_at": "2026-10-09T01:36:19.038Z",
      "location_count": 22,
      "location_summary": "Fayetteville, Arkansas • Jonesboro, Arkansas • Little Rock, Arkansas + 18 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00258895"
    },
    {
      "nct_id": "NCT02199691",
      "title": "Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Meningitis",
        "Meningococcal Meningitis",
        "Meningococcal Infections"
      ],
      "interventions": [
        {
          "name": "Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Meningococcal (Groups A, C, Y and W135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "10 Years to 17 Years"
      },
      "enrollment_count": 1715,
      "start_date": "2014-07-22",
      "completion_date": "2015-10-02",
      "has_results": true,
      "last_update_posted_date": "2022-04-04",
      "last_synced_at": "2026-10-09T01:36:19.038Z",
      "location_count": 35,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Downey, California + 28 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Miami Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02199691"
    },
    {
      "nct_id": "NCT00715910",
      "title": "The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Adolescents/Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Infections, Meningococcal"
      ],
      "interventions": [
        {
          "name": "Nimenrix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Blood sampling",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "15 Years to 30 Years"
      },
      "enrollment_count": 818,
      "start_date": "2008-07",
      "completion_date": "2013-10",
      "has_results": true,
      "last_update_posted_date": "2014-11-27",
      "last_synced_at": "2026-10-09T01:36:19.038Z",
      "location_count": 10,
      "location_summary": "Daly City, California • Fairfield, California • Redwood City, California + 6 more",
      "locations": [
        {
          "city": "Daly City",
          "state": "California"
        },
        {
          "city": "Fairfield",
          "state": "California"
        },
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Vallejo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00715910"
    }
  ]
}